Researchers turn mouse into factory for human liver cells

August 9, 2007

Oregon Health & Science University researchers have figured out how to turn a mouse into a factory for human liver cells that can be used to test how pharmaceuticals are metabolized.

The technique, published in the journal Nature Biotechnology, could soon become the gold standard not only for examining drug metabolism in the liver, which helps scientists determine a drug's toxicity. But it also can be used as a platform for testing new therapies against infectious diseases that attack the liver, such as hepatitis C and malaria.

"This has the potential, if it becomes easy to use and widely available, to change the way drugs are tested," said study leader Markus Grompe, M.D., professor of molecular and medical genetics, and pediatrics, OHSU School of Medicine.

"In terms of fostering research, this will be great for malaria, this will be great for hepatitis, this will be great for liver stem cells, this will be great for gene therapy. It will allow a lot of what's going on only in rodents to be taken into a much more clinical setting. So I'm very happy about it."

Arundeep S. Pradhan, director of OHSU's Technology & Research Collaborations office, which is responsible for transferring the university's research discoveries to the commercial sector, said market demand for Grompe's discovery is high. OHSU has filed a patent application on the technology and, in cooperation with Grompe, has spun it off into a Portland-based start-up company named Yecuris through the university's Springboard Program.

"Yecuris is a viable start-up company based on significant developments at OHSU," Pradhan said. "The products developed by Yecuris have the potential to ease one of the bottlenecks in drug development: the testing of drugs for liver toxicity."

The worldwide market for human liver cells the pharmaceutical industry uses for testing candidate drug compounds is estimated at $2 billion a year, according to a business plan for Yecuris. That's because the liver is the principal site for the metabolism of drug compounds.

"Chemicals are converted to other chemicals in the liver, and you can't predict how the compound you developed in the lab will be converted," Grompe said. "Often, it's not the drug that's toxic, but the resulting metabolites. The conversion of drugs cannot be predicted with any current technology, such as computer models. You actually have to see what human liver cells do with any given drug."

And human liver cells must be used instead of cells from laboratory animals because liver enzymes that break down these compounds are species specific. "Animal liver cells process drugs quite differently than human liver cells do," he said.

Another obstacle for drug companies is the human liver cell market is filled with poor-quality or nonviable cells isolated primarily from human cadaver livers left over after high-quality livers needed for transplants are harvested. Plus, the cells are only available when specimens become available, which can be any hour of the day or night, and they must be used immediately.

"There are a number of companies that take these leftover livers, process them and ship the cells to people who need them for testing," Grompe said. "You have no control over when you get them, and you have no control over the quality when you get them. Many batches of cells are bad, low quality." And human liver cells from living sources are difficult to expand in laboratory tissue cultures.

In the last decade, scientists have studied whether mice could be genetically engineered and bred to grow human liver cells. Early results since 2004 showed it could be done, but the mice were difficult to breed, the time window for transplanting human liver cells into the mice was narrow, and the mouse liver, despite efforts to make the animal immunodeficient, often rejected the human cells.

Grompe's laboratory now has a system in which those disadvantages have been engineered out. It has created a severely immunodeficient mouse strain that develops liver disease only when the animals don't receive a protective drug called NTBC, allowing liver disease to be turned on and off.

"Our mice on this medicine are perfectly healthy, normal mice, and only when we take them off the NTBC do they get liver disease," Grompe said. "It's an easy system that any research lab should be able to set up, which is very different from what's around now."

In fact, the human liver cells from the repopulated mouse livers are indistinguishable from normal human liver cells, according to the study. "The healthy human liver cells take over and replace the sick mouse liver cells," Grompe said. "You end up with a healthy mouse that makes human blood clotting factors, all the proteins the liver makes, human bile, everything."

The mice also retain their unique traits for multiple generations, and each mouse can be implanted with human liver cells at least four times. Grompe estimates that each round of implantation can generate more than 20 million viable human liver cells.

"We think we will have a real edge in terms of quality and availability of cells," Grompe said. "We have a product. All we need to do is scale up and start selling it to anyone who wants to buy it."

In the coming months, Grompe's lab will develop a library of human liver cells from common variations of human drug metabolism. "Different humans metabolize drugs differently. So we want to create a library of cells from different humans to capture some of that variability," Grompe said.

Source: Oregon Health & Science University

Explore further: Cell therapy, now artisanal and costly, heads for mass production

Related Stories

Cell therapy, now artisanal and costly, heads for mass production

October 12, 2018
Not so long ago, manipulating living cells to serve as therapies was a difficult and mysterious art. Only a few biomedical companies and academic labs could claim proficiency.

Stem cells will 'change medicine forever,' says UB surgeon-turned-stem cell engineer

October 9, 2018
Natesh Parashurama, MD, Ph.D., assistant professor of chemical and biological engineering at the University at Buffalo, has made his life's mission the translation of stem cell research from the laboratory to patients.

Nutrients may reduce blood glucose levels

October 10, 2018
Type 2 diabetes is driven by many metabolic pathways, with some pathways driven by amino acids, the molecular building blocks for proteins. Scientists at Joslin Diabetes Center now have shown that one amino acid, alanine, ...

Low copper levels linked to fatter fat cells

October 11, 2018
In studies of mouse cells, Johns Hopkins researchers have found that low levels of cellular copper appear to make fat cells fatter by altering how cells process their main metabolic fuels, such as fat and sugar.

Invasive breast cancers punch tunnels into neighboring tissue

October 9, 2018
Cancers pose the greatest danger when they become invasive and then spread from their originating tissues throughout the body.

The pentagon and the bean—redrawing the structure of an immune system protein

October 10, 2018
Researchers have revealed the structure of an essential immune protein, creating future possibilities to develop more effective medicines for a range of illnesses from cancer to neurological diseases. University of Tokyo ...

Recommended for you

Student develops microfluidics device to help scientists identify early genetic markers of cancer

October 16, 2018
As anyone who has played "Where's Waldo" knows, searching for a single item in a landscape filled with a mélange of characters and objects can be a challenge. Chrissy O'Keefe, a Ph.D. student in the Department of Biomedical ...

Researchers use brain cells in a dish to study genetic origins of schizophrenia

October 16, 2018
A study in Biological Psychiatry has established a new analytical method for investigating the complex genetic origins of mental illnesses using brain cells that are grown in a dish from human embryonic stem cells. Researchers ...

Why heart contractions are weaker in those with hypertrophic cardiomyopathy

October 16, 2018
When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and affects an estimated 1 in 500 ...

Importance of cell cycle and cellular senescence in the placenta discovered

October 15, 2018
Working with researchers from Stanford University and St. Anna Children's Cancer Research, researchers from Jürgen Pollheimer's laboratory at the Medical University of Vienna's Department of Obstetrics and Gynecology have ...

Team's study reveals hidden lives of medical biomarkers

October 12, 2018
What do medical biomarkers do on evenings and weekends, when they might be considered off the clock?

Researchers find a 'critical need' for whole genome sequencing of young cancer patients

October 12, 2018
St. Jude Children's Research Hospital has re-defined the gold standard for diagnostic testing of childhood cancer patients in the precision-medicine era and has implemented the testing for new cancer patients. The findings ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.